Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Every year millions of people die because of these viral infections. There is high scope for R&D for development of treatment in the Viral Infections Market.
Scope and Regional forecast of the Viral Infections Market:
The Global Viral Infections Market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.
North America leads the Viral Infections Market with high capital expenditure for research and development of treatment for various viral infections. Many companies are competitively investing and researching to find effective treatment solution for HIV, hepatitis and other types of diseases caused by virus.
Asia Pacific is the largest region in the Viral Infections Market. Since, this region is highly populated; there is a high demand for viral infection treatments and drugs in the region. There is huge scope for more application of new techniques and therapies through 2021.
Europe his expected to witness high demand for treatment in the Viral Infections Market. Viral infections are more complicated than bacterial infection, but bacterial infection symptoms are similar to symptoms by virus.
Complete research on Viral Infections Market available at http://www.marketintelreports.com/report/gbihc406mr/global-viral-infections-market-to-2021–promising-new-competitors-and-expanding-treatment-population-to-offset-increased-uptake-of-generics
Segmentation and key players of the Viral Infections Market:
The Viral Infections Market is segmented into various categories by viral infection type, by treatment, by marketed products, by pipeline, by clinical trials, by assessment of key pipeline products and by geography.
By viral infection type: Human Immunodeficiency Virus (HIV), Hepatitis C Virus, Hepatitis B Virus and Influenza
By treatment: vaccines and antiviral agents
By marketed products:
Multiple indications: Viread – Gilead, Epivir/Epivir-HBV – ViiV Healthcare and Pegasys – F. Hoffmann La Roche
Human Immunodeficiency Virus (HIV): Truvada – Gilead, Atripla – Gilead, Stribild – Gilead, Tivicay – ViiV Healthcare, Triumeq – ViiV Healthcare and Genvoya – Gilead
Hepatitis C Virus (HCV): Olysio – Janssen, Sovaldi and Harvoni – Gilead and Zepatier – Merck and Co.
Hepatitis B Virus: Baraclude – Bristol-Myers Squibb
Influenza Virus: Tamiflu – Roche
By pipeline: pipeline products by stage of development and molecule type, pipeline products by molecular target
By clinical trials: clinical trial failure rates, clinical trial duration, clinical trial size and cumulative clinical trial size
By assessment of key pipeline products: Sofosbuvir in Combination with Velpatasvir – Gilead, Tenofovir alafenamide fumarate – Gilead, Descovy – Gilead, Cobicistat, darunavir, emtricitabine and TAF – Johnson & Johnson, Beclabuvir hydrochloride – Bristol-Myers Squibb and V-212 – Merck
By geography: North America, South America, Europe, Asia Pacific and ROW
Order a copy of Viral Infections Market report @ http://www.marketintelreports.com/purchase.php?id=gbihc406mr
The key players in the Viral Infections Market are as follows:
- Johnson & Johnson
- Bristol-Myers Squibb
- Merck & Co.
The Viral Infections Market is a rapidly growing market with high potential in the global market. High investment for R&D and drug production is made by many companies and pharmaceuticals across the globe.
The Viral Infections Market is expected to witness high growth owing to the increasing population affected with viruses and high demand for drugs through 2021.
Check research sample here http://www.marketintelreports.com/pdfdownload.php?id=gbihc406mr
On a related note, another research on
Ebola Viral Infections – Pipeline Review, H1 2016 @ http://www.marketintelreports.com/report/gmdhc8001idb/ebola-viral-infections–pipeline-review-h1-2016
Epstein-Barr Viral Infections Global Clinical Trials Review, H2, 2015 @ http://www.marketintelreports.com/report/gdhc3168ctidb/epsteinbarr-viral-infections-global-clinical-trials-review-h2-2015
MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.
MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Company Name: MarketIntelReports
Contact Person: Mayur S.
Address:2711 Centerville Road, Suite 400
Country: United States